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ABSTRACT 
 
Cervical cancer is the leading cause of cancer related morbidity and mortality in women in 
Tanzania. The impact of HIV/AIDS epidemic to cervical precancerous lesions and invasive 
cervical cancer has a significant implication, for any public health concern, especially in one 
of the most prevalent areas like Morogoro Region, in Tanzania. A comparative retrospective 
study of 536 women screened for cervical cancer disease by visual inspection methods at 
the Morogoro Regional Referral Hospital for 3 years and grouped according to their HIV 
status was done. The prevalence of precancerous lesions was 55.5% in HIV positive women 
and 14.7% in HIV sero negative women. Furthermore, the prevalence of extensive or large 
precancerous lesions was 52.5 % in HIV positive women and 25% in HIV sero negative 
women.In addition, the prevalence of invasive cervical cancer was 50.8% in HIV sero 
negative women compared to 26.7% in HIV positive women.The risk factors for the 
extensive/large cervical lesions and suspicious of cervical cancer disease were HIV positive 
status (OR 3.4, 95% CI 1.7-6.8, p<0.001), CD 4 T-cells count less than 300 cells/mm3(OR 
4.7,95% CI 0.86-31.07,p =0.0352), high parity ( OR 3.3,95% CI 1.89-5.79, p <0.001 ), and 
age above 45 years (OR 3.25,95% CI 1.81-5.85, p <0.001) .Therefore, HIV/AIDS has a 
highly statistical significance association (p <0.001) and high influence on the development 
of cervical precancerous lesions in HIV positive women, however it’s direct involvement in 
the progression to the invasive cervical cancer especially in the HAART era is questionable.  
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RESUMO 
 
O cancro do colo do útero é a principal causa de morbilidade e mortalidade associada ao 
cancro em mulheres na Tanzânia. A infecção  por VIH/SIDA tem implicações significativas 
nas lesões pré-cancerígenas do colo do útero e na respectiva neoplasia invasiva. Dada a 
extensão que esta epidemia contabiliza, ela assume-se como um verdadeiro problema de 
saúde pública, particularmente grave nas áreas mais prevalentes da doença, como é o caso 
da região de Morogoro na Tanzânia. Foi realizado um estudo retrospectivo comparativo 
durante 3 anos, em 536 mulheres rastreadas para a presença de cancro do colo do útero, 
diagnosticado por métodos de inspecção visual no Morogoro Regional Referral Hospital. As 
participantes foram agrupadas de acordo com a sua condição para o vírus VIH. A 
prevalência de lesões pré-cancerígenas foi de cerca de 55,5% em mulheres positivas para 
a presença do vírus VIH e cerca de 14,7% em mulheres VIH seronegativas. Além disso, a 
prevalência de lesões pré-cancerígenas extensas ou grandes foram detectadas em cerca 
de 52,5% das mulheres VIH seropositivas e apenas em cerca de 25% das mulheres VIH 
seronegativas. No entanto, a prevalência de cancro do colo do útero invasivo foi reportada 
em cerca de 50,8% das participantes VIH seronegativas, enquanto ao passo que uma 
condição clínica idêntica foi verificada em cerca de 26,7% das mulheres positivas para a 
presença do vírus VIH. Os factores de risco identificados  à existência de lesões extensas 
ou grandes no colo do útero e consequente suspeita da neoplasia que lhe está associada 
foram seropositividade para o vírus VIH (OR 3,4; 95% IC 1,7-6,8; p<0,001), contagem de 
células T CD4+ menor que 300 células/mm3 (OR 4,7; 95% IC 0,86-31,07; p=0,0352), 
elevada paridade (OR 3,3; 95% IC 1,89-5,79; p<0,001) e idade acima dos 45 anos (OR 
3,25; 95% IC 1,81-5,85; p<0,001). De acordo com os nossos resultados, a influência do 
VIH/SIDA, nomeadamente entre mulheres VIH seropositivas, e o desenvolvimento de 
lesões pré-cancerígenas do colo do útero, representa uma associação estatisticamente 
relevante (p<0,001). No entanto, o envolvimento directo do vírus VIH na progressão para 
cancro invasivo do colo do útero, especialmente na era HAART, permanece não conclusiva. 
 
(Palavras-chave: Lesões pré-cancerígenas do colo do útero; Cancro do colo do útero invasivo; VIH; 
Métodos de inspecção visual) 
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CHAPTER 1 
 
1.0 INTRODUCTION 
1.1 Background  
Each year, more than 530,000 women worldwide are diagnosed with cervical cancer and 
around 275,000 die from the disease, with 88% of deaths occurring in developing countries 
especially in sub Saharan Africa [1]. 
 
Cervical cancer disease is a fully preventable and curable disease at low cost and at low 
risk, when early screening to facilitate the timely detection of precancerous lesions in 
asymptomatic women is available together with appropriate diagnosis, treatment and follow-
up [1, 2]. However, with the introduction of HPV vaccine, the burden of the disease is very 
low in developed countries, while the situation is quite the reverse in developing countries 
where it constitutes a major public health problem due to genital cancers in women [1-3]. 
 
Several cancers have been designated as AIDS related, with a significantly increased risk 
among people living with HIV [4]. Cervical cancer is recognized as a sexually transmitted 
disease [5]. The sexually transmitted aetiological agent has been identified as the human 
papillomavirus [4, 5]. Women with HIV infection are more likely to have a concurrent HPV 
infection [4]. There is firm evidence, however, that HIV is independently associated with an 
increased risk of cervical intraepithelial neoplasm [6]. Some studies suggest that HIV 
infection is associated with the rapid progression of HPV induced cervical pre-malignant 
lesions to invasive cervical cancer [7]. 
 
Tanzania has among the highest incidences of cervical cancer disease and HIV/AIDS cases 
in the world with concomitant high mortality affecting women at their prime [1, 8].The 
association between HIV and invasive cervical cancer is complex, with several studies 
clearly demonstrating an increased risk of precancerous cervical lesions and a more rapid 
progression to invasive cancer, amongst HIV infected women [7, 9]. 
 
Regular screening with a Pap smear has been shown to effectively lower the risk of 
developing invasive cervical cancer, by detecting precancerous changes earlier 
[10].However, in developing countries, only about 5% of eligible women undergo cytology-
based screening in a 5-year period [11]. This is because there are too few trained and skilled 
professionals to implement such programs effectively in developing countries like Tanzania 
[12]. In addition, healthcare resources are not available to sustain such programs [11]. In 
virtually all developing countries, cytology-based services are confined to teaching hospitals 
or private laboratories in urban areas [13]. Furthermore, delays in reporting cytology results 
make it less likely that test positive women ever receive their results on time, hence delay in 
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treatment or loss in follow-up within a very short duration [13]. These are some of the 
barriers that prevent cytology-based screening programs from being effective in developing 
countries. 
 
Recent studies have demonstrated that visual inspection with acetic acid or with Lugol’s 
iodine are alternatives of sensitive cervical cancer screening methods [14]. The procedures 
are cheap and non-invasive, and can be done in a low level health facility like a health 
centre [14]. More importantly, both provide instant results and those patients eligible for 
treatment can receive the treatment of the precancerous lesions using cryotherapy on the 
same day and in the same health facility [15]. These “see and treat” methods ensure 
adherence to treatment soon after diagnosis, hence decreases the late presentation of the 
disease [11, 15]. 
 
Cryotherapy as a method of treatment for precancerous lesions is effective and easier to 
implement than other treatment modalities such as loop electrosurgical excision procedure , 
loop excision of the transformation zone  and cone biopsy [16]. Furthermore, it has 
additional advantages, including the facts that it is affordable; there are no need for 
complicated equipment and it can be done by less specialized personnel and thus can be 
implemented in a primary health-care setting [16].Secondary prevention of cervical cancer 
through screening and treatment of cervical precancerous lesions is associated with an 
overall reduction in morbidity and mortality due to cervical cancer disease [1]. 
 
Moreover, lack of sustainable screening programs for early detection of precancerous 
lesions, HPV vaccination program and functional cancer registries in Tanzania is currently 
unforeseen situation which has to be directed [1, 3, 8]. Most screening activities are done as 
pilot studies or research projects which are discontinued on completion [1]. Generally, the 
coverage of cervical cancer screening remains very poor especially in the remote areas [17] 
like Morogoro region where the impact on invasive cervical cancer is very prominent while 
the prevalence of the disease is still unknown [1, 8, 18]. 
 
For example, despite the high burden of the disease, cervical cancer prevention services in 
the country, are not readily available to a majority of women [19] . Cytology based screening, 
HPV vaccination and HPV DNA self-sampling methods as used in high-income countries 
[17] [20], are currently not feasible in Tanzania, because of the financial, infrastructure, 
human resources and technological investments required[19]. Tanzania also lacks adequate 
histopathology laboratories, other diagnostic and treatment facilities for cervical cancer in 
regional hospitals [19] including Morogoro Regional Referral Hospital. Yet, opportunities do 
exist to prevent, cure and relieve suffering, by promoting primary and secondary prevention, 
as well as tertiary care [21]. In addition, with the onset of HIV/AIDS epidemic which is very 
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high in Tanzania and so the Sub Saharan Africa region as a whole, there is a growing 
evidence that it has elevated the problem of cervical cancer to a serious level and the exact 
prevalence and the outcome of the disease for the people living with HIV especially in 
upcountry areas is ambiguous [19]. 
 
For instance, in Uganda, where the incidence of HIV/AIDS is very high among East African 
countries, Parkin et al [22] reported a marked increase in the incidence of cervical cancer 
cases since the nineteen eighties, with stabilization in the nineteen nineties. In the WHO 
world cancer report 2012 [1] on HIV/AIDS, there were more than 8 million people living with 
HIV in low and middle income countries at the end of 2011. This was a 20-fold increase in 
the number of people living with HIV in developing countries between 2003 and 2011, and a 
20% increase in just one year (from 6.6 million in 2010 to more than 8 million in 2011) [1]. 
 
Summing up, there must be an evaluation of available data on current cervical cancer 
screening programs in both HIV infected women and non HIV infected women in order to 
draw the conclusion and recommendations on the impact of HIV/AIDS pandemic [23] to the 
development of invasive cervical cancer disease so as to change the strategies to tackle the 
disease under new threat of increasing HIV infections in women especially in rural areas like 
Morogoro region [1, 24]. 
 
1.2 Problem statement 
HIV/AIDS epidemic in sub-Saharan Africa, which equally affects Tanzania with high HIV 
prevalence rate of 6.8% in 2007 being women aged 15–49, has significant implication, for 
any public health concern, attempting to address the burden of the disease on the invasive 
cervical cancer in the country [19]. 
 
Tanzania, being one of the Sub Saharan regions, the country has among the highest 
incidences of cervical cancer disease and HIV/AIDS cases in the world with concomitant 
high mortality affecting women at their prime [1, 8].The association between HIV and 
invasive cervical cancer is complex, with several studies demonstrating an increased risk of 
precancerous cervical lesions and a more rapid progression to invasive cancer, amongst 
HIV infected women especially in young ages [7, 9]. The vast majority of cervical cancer 
patients is usually seen only at a late stage of evolution of the disease, which reduces 
considerably the chances of survival [19]. 
 
Currently, there are no published data on the burden of the disease in Morogoro region [25]. 
In addition, the impact of HIV/AIDS to cervical cancer has not been determined regardless of 
the increase in the number of invasive cervical cancer cases in young women in the eastern 
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zone of Tanzania, specifically in Morogoro region, one of the most HIV/AIDS prevalent 
regions [19]. 
 
1.3 Justification 
Tanzania is a developing country, despite of a population of approximately 48 million people 
and a country size of 945,087 square kilometres, it has only one major cancer treatment 
centre with few documented cancer registries for more than 53 years of independence [19].  
 
The determination and comparison of the current prevalence, risk factors, methods of 
screening, treatment protocols and their outcome in patients with cervical precancerous 
lesions, cervical cancer and their HIV status at MRRH will lead to the determination of the 
effects of the two diseases and hence initiation of a benchmark of continuous screening 
program, proper follow up of the patients and treatment protocols by using the minimum 
resources we have, which is a very crucial step in the implementation of a cancer registry in 
Morogoro region. 
 
Another reason is to have concrete data, knowledge and research so that convey the new 
strategies to combat cervical cancer disease in the region, according to the new challenges 
of HIV/AIDS epidemic. The outcome seen in this study will help to shift the current focus 
towards more preventive strategies like implementation of continuous cervical cancer 
screening and treatment in all HIV/AIDS clinics, HPV vaccination for all girls before sexual 
debut and massive community cervical cancer screening campaign in Morogoro region as a 
whole. 
 
Finally, the impact of this implementation will decrease the number of referrals, advanced 
cases of cervical cancer disease, increase awareness of the disease to the society and 
policy makers, hence gradually it will reduce the overall high mortality due to cervical cancer 
in the region. 
 
1.4 Research Question 
What is the influence of HIV/AIDS on cervical precancerous lesions and invasive cervical 
cancer in Morogoro region? 
 
1.4.1 Objectives 
1.4.2 Broad objective 
To determine the influence of HIV/AIDS on prevalence and risk factors for cervical 
precancerous lesions and invasive cervical cancer among HIV infected women at MRRH. 
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1.4.3 Specific objectives 
i)  To determine the prevalence of cervical precancerous lesions among HIV infected 
women at MRRH. 
ii)      To determine the percentage and risk factors/determinants for extensive/large  
         cervical precancerous lesions among HIV infected women at MRRH. 
iii)    To determine the prevalence of ICC among HIV infected women at MRRH. 
 
 
 
 
 
 
6 
 
 
 
CHAPTER 2 
 
2.0 LITERATURE REVIEW 
2.1 Epidemiology 
2.1.1 Epidemiological link between the two pandemics 
Tanzania suffers one of the highest cervical cancer burdens in the world and the highest in 
East Africa, with an age-standardized incidence rate of 50.9 cases per 100,000 women and 
an ASR mortality  of 37.5 per 100,000 women[19]. In 2009, cervical cancer accounted for 
35.3% of all cancer patients seen at the ORCI, the only specialized facility for cancer 
management in Tanzania [26].There is a lot of evidence that HIV infection enhances HPV 
carriage in a single individual [1].Cervical cancer incidence rates are lowest in Western Asia 
and highest in East Africa [1, 27]. As a consequence, HIV also has an impact on HPV 
infection within couples [27]. Among heterosexual couples living in South Africa, HIV 
negative male partners of HIV positive women had a significantly higher rate of HPV penile 
carriage than partners of HIV negative females (58 vs 32% respectively; p=0.001) and the 
prevalence was further increased to 72% when both partners were HIV positive 
[28].Furthermore, type-specific sharing of HPV within the couple was also associated with 
HIV co-infection [28].   
 
According to two large meta-analyses, one performed in women from the general population 
and the other in HIV infected women, HPV prevalence was higher within the same region in 
women with HIV compared with women without HIV. When comparing the HPV infection 
rates and incidence rates from different world regions, the highest prevalence was found in 
regions where HIV infection was more prevalent, according to the WHO data, such as sub-
Saharan Africa (Figure 1) [1, 28] . 
 
The age-standardized incidence of cervical cancer is the highest in Sub-Saharan Africa and 
varies from 23/100,000 woman-years to 34.5 in Eastern Africa compared with <10 in 
Western Europe and North America [1, 27, 28]. For example the world’s highest age-
standardized death rates from invasive cervical cancer were 67 per 100 000 people in 
Harare, Zimbabwe and 40.8 per 100 000 in Kampala, Uganda in 1997 [15, 27]. 
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Figure 1:   HPV infection prevalence in the cervix and invasive cervical cancer incidence 
according to WHO HIV sero-prevalence distribution in 2010 (Adopted from [1]). 
 
 
2.1.2 HPV, HIV infection and cervical cancer  
Persistence infection with oncogenic HPV has been established as a necessary causal 
factor for cervical cancer [29]. Harald zur Hausen, postulated in the early seventies that HPV 
infection was the causative agents and it were proved in the eighties with advanced 
technologies to detect the viral genome [28]. 
 
Apart from vertical transmission and blood transfusion, the main route of transmission of 
HPV and HIV is sexual intercourse [28, 30]. Many women get exposed to HPV, but very few 
develop into cervical cancer[31].This implies that there are other co-factors at play in the 
carcinogenic process [28].Behavioral and biological determinants include number of sexual 
partners, the sexual behaviour of male partner, the age at first sexual intercourse, high 
parity, smoking, long-term use of hormonal contraceptives, nutritional status and vaginal 
micro flora [18, 24]. HPV co-infection with other sexually transmitted diseases such as HIV, 
Chlamydia trachomatitis and Herpes simplex virus type 2 increases the risk of developing 
cervical cancer disease [28, 31]. 
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However, there are some arguments on this causal role of HSV-2 in cervical cancer onset 
that many studies which concluded this did not control for the role of HPV [9]. 
Immunosuppression, which is caused by HIV and organ transplantation, has been 
associated with multiple infections with HPV persistence and progression from pre-malignant 
lesions to cancer [28, 32]. HPV oncoproteins E6 and E7 (Figure 2) inhibit the action of p53, 
and pRB preventing human DNA repair, as cellular replication is no longer controlled, DNA 
errors and chromosomal mutations accumulate that may cause the emergence of tumour 
cells [32]. 
 
On the other hand, HPV has the capability to escape from immune defences, as it does not 
induce cell death or viraemia and when it replicates, new virions are released far from the 
immune system in terminally differentiated epithelial cells of the mucosa [31]. This induces a 
weak or nonexistent antibody response [32]. There are approximately 40 different HPV 
genotypes affecting the human anogenital tract (cervix, vulva, vagina, penis and anus) [24, 
32, 33]. These genotypes are divided in low-risk HPV (mostly types 6 and 11) responsible 
for benign warts or condylomas, which are nonmalignant tumours and high-risk (HR) HPV 
(mostly types 16 and 18, and less frequently types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 
68) are responsible for malignant disease [32].Infection with HPV is very frequent in human 
beings, with a lifetime infection risk of at least 80% [33, 34]. Different type-specific HPV 
infections occur early during the first sexual intercourses and are transient for most 
individuals [32] . 
 
Nonetheless, 5–10% of women harbour persistent cervical infection with HR HPV and will 
thus be at risk of developing high-grade (HG) squamous intraepithelial lesions (SIL) in their 
third or fourth decade of life. HG SIL, also called HG dysplasia, is the stage just before 
cancer on cytological samples [35, 36]. 
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Figure 2: The Human papillomavirus life cycle (Adapted from [37]). 
 
2.1.3 Cervical precancerous lesions 
Richart classification uses cervical intraepithelial neoplasia (CIN) [5, 14].The Bethesda 
classification uses squamous intraepithelial lesions (SIL) [5].Lesions are classified 
histologically in accordance to the degree of neoplastic progression with a scale ranging 
from CIN 1 to CIN 3 or carcinoma in situ (CIS) by Richart classification [14].                      
The corresponding grades I Bethesda classification is low grade SIL(LGSIL), for CIN1 and 
high grade SIL(HGSIL) for CIN2 and CIN3 [14, 38].Atypical cells of unknown significance 
(ASCUS) refer to unclear abnormal findings which may be due to neoplastic changes, 
inflammations or non-infective processes [5, 14, 36]. 
 
Many studies of precancerous lesions of the cervix have reported regression in LGSIL in 
over 60% and progression to cancer about 1%, regression of CIN2 of 40% and progression 
to cancer about 5%, regression of CIN3 of 30% and progression to cancer by 12% [30].The 
average modal time from infection with HPV to CIN3 has been estimated to be 10 years 
(Figure 3) and from CIN3 to invasive cancer averaging 10 to 15 years [14]. 
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Figure 3: The diagram to show the natural history of HPV infection to precancerous lesions 
and the invasive cervical cancer. 
 
2.2 HIV favouring HPV Infection 
HIV infection favours HPV at the molecular and cellular levels such, as penetration of HPV in 
the target cells, HPV replication and HPV immune escape from host defences [31, 39]. 
 
In cervical epithelial cells from HIV-uninfected patients, the adjunction of HIV proteins (tat 
and gp120) with cytokines produced by HIV-infected cells (TNF-α and IFN-γ) induced the 
disruption of epithelial tight junctions and potentiated HPV penetration into the basal 
epithelial cells, which are HPV targeted cells [30, 31, 39]. 
 
HIV tat protein during HPV replication showed to significantly enhance HPV transcription 
and thus the expression of the HPV E oncogenes and L capsid proteins in cell cultures [28, 
32, 33].To escape immune surveillance, HPV is able to induce a shift to T helper-type (Th) 
polarization from Th1 to Th2, with a parallel shift in cytokine production [39, 40].  
 
Again, HIV favours HPV infection at the clinical level by increasing the new acquisition of 
HPV 16 [40]. HIV and HPV share a common route of transmission, unprotected sex with 
multiple partners [39]. Moreover, HPV infection is further increased by progressive 
immunosuppression during HIV course [40]. This results in HIV infected individuals with 
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higher HPV viral loads (VLs) than HIV uninfected individuals [41, 42], less HPV clearance 
and more frequent HPV persistent infection [6]. Reactivation of latent HPV infection is more 
frequent in HIV positive patients with lower immunity levels [6, 39, 40].  
 
In heterosexual couples lived in South Africa, showed that HIV positive status was 
associated with a significantly increased risk (2–3 times) of new detection of HPV in both 
men and women [43]. Meanwhile, the chance to clear HPV infection was reduced in HIV 
positive men and women compared with HIV negative individuals (relative risk [RR]: 0.71; 
95% CI: 0.55–0.93 in men and RR: 0.46; 95% CI: 0.34–0.62 in women) [28]. 
 
In another cohort study of 652 HIV positive women of African origin lived in Europe, the 
incidence rate of new HR HPV infections of the cervix was 13.4, contrasting with the five per 
100 woman-years found in HIV-negative women with similar age and cytology [18].  
Similarly, in the same study, for each increase of 100 CD4 cells/μl, there was a proportional 
significant decrease in the risk of carrying HR HPV with an odds ratio of 0.82 (95% CI: 0.76–
0.89, p < 0.001) [18, 33, 39]. 
 
Many studies found that, higher HIV VL is associated with a significantly increased carriage 
of HPV and of SIL independently from CD4+ T-cell count decrease [43, 44]. HIV viraemia 
has shown to be an independent predictive factor for other opportunistic infections by 
inducing immune defects other than depletion of CD4+ T-cell count, such as cytokine 
production alterations which was notably modified in HIV positive patients [44]. 
 
Another recent study showed that, the risk of newly detected cervical HR HPV was 
increased by 2.5–5 times within 3–6 months after acquiring HIV infection [44]. This may 
reflect the highest rate of HPV latent infection reactivation already demonstrated in HIV 
positive patients [44]. 
 
In addition, another study showed that, HIV positive adolescents with >500 CD4+ T cells/μl 
had a significantly higher rate of persistent HR HPV than HIV-negative controls, illustrating 
that even slight changes in immune function might be responsible for higher HR HPV 
prevalence in HIV-positive patients [18, 28, 33]. 
 
HPV prevalence was 45% for any HPV genotypes and 31% for HR genotypes in 305 HIV-
infected men who had sex with men (MSM) in Taiwan compared with 18% and 13%, 
respectively, in the HIV uninfected MSM. In the same study, decreasing CD4+ T cell count 
was strongly associated with increasing prevalence of HPV including HR types [44]. 
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Similarly to what has been largely demonstrated in the genital area, HPV infection is also 
more important in the oral area of HIV infected individuals [43]. For instance, among 249 HIV 
positive patients from Australia, HPV prevalence was 19% for all HPV genotypes and 4.4% 
for HPV16 compared with HPV 7, and 0.8% in 251 HIV negative patients [43]. In another 
study, the mean HPV VL found in saliva samples was 20-times higher in HIV infected 
patients (p < 0.001) [45]. 
 
2.3 HIV favouring HPV-induced Lesions 
The incidence of cervical biopsy-confirmed SIL was found to be 8.3/100 person-years in 
HIV-positive women compared with 1.8/100 person-years for HIV-negative women [39, 43]. 
 
Moreover, regression of warts or SIL can be achieved by a CD4+ T cell response against 
HPV antigen such as E6 and E7 oncoproteins, but this immune response is impaired during 
the course of HIV infection [32].In a case–control study, abnormal pap smear after 
conization was more frequent in women with HIV, 62% compared to 33% in HIV uninfected 
women and there was HG SIL recurrence in 20% compared with none in women without HIV 
[18, 28, 33, 39]. 
 
In MSM, the pooled prevalence of HG AIN proved by biopsy was 29% compared with 22% in 
HIV uninfected MSM [34]. In the same meta-analysis, anal cancer incidence was 46/100,000 
HIV positive MSM per year versus 5.1 in HIV negative MSM [39, 40]. 
 
In a cohort of 500,000 HIV patients linked to the national US cancer registry, the incidence of 
cervical and anal cancer were significantly increased in HIV-positive patients (ICC is 6–10 
times more frequent than in the general population) [18, 33, 43]. 
 
2.4 HPV infection favouring HIV acquisition 
The risk of acquiring HIV was doubled when the infection by any HPV genotype was present 
prior to HIV infection [39, 40]. In addition, the risk of HIV acquisition increased significantly if 
there was a previous infection with two or more HPV genotypes in the same individual 
(hazard ratio: 3.5; 95% CI: 1.02–10.06; p= 0.002) [40].  
 
As other STIs are known to be associated with increased HIV acquisition, HPV infection and 
induced lesions could disrupt the mucosal epithelia integrity, allowing HIV to enter more 
easily [18, 33].Similarly, the E7 protein of HPV16 has been shown to potentiate increased 
permeability of genital mucosa to HIV by down regulating an epithelial adhesion molecule 
called E-cadherin [32, 33]. 
 
13 
 
 
HIV acquisition, on the other hand, was significantly higher in women with HPV detection 
loss just before acquiring HIV compared with women with persistently detectable HPV 
infection, odds ratio was 5.4 (95% CI: 2.4–9.9, p< 0.001) [33]. This hypothesis has been 
confirmed in a case–control study done in heterosexual males included in a circumcision trial 
[46]. 
 
In cases of other concomitant STIs, cells susceptible to HIV infection are recruited to the 
surface of the mucosa [46, 47]. The results of a case–control study in Zimbabwe, showed 
that, during the 22 months of follow-up, 154 women acquired HIV while 479 remained HIV 
uninfected [35]. After controlling for behavioural and biological covariates such as other 
STIs, the cervical infections with HPV raised the risk of acquiring HIV infection by a 2.4-fold 
(p<0.001, 95% CI, 1.5–4) and the risk was enhanced with increasing numbers of HPV types 
isolated in the same individual [35]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
 
 
CHAPTER 3 
 
3.0 METHODOLOGY 
3.1 Study Area and Duration 
This study was conducted at MRRH obstetrics and gynaecology department from 1st 
January, 2010 to 31st December, 2013.The hospital is situated in the eastern zone of 
Tanzania, about 1 Kilometre north of Morogoro municipality. It is the referral hospital for the 
whole region. The hospital has a bed capacity of 500 and serves about more than 15,000 
patients per year. According to the 2012 national census, the region had a population of 
2,218,492 with the region's 2.4 percent average annual population growth rate. It was also 
the 22nd most densely populated region with 31 people per square kilometre [8]. 
 
3.2 Study design 
A comparative retrospective study of patients who were screened for cervical cancer 
disease by visual inspection using acetic acid or Lugol’s iodine at the hospital, according to 
their HIV status and followed up for further pathological diagnosis for those who were 
referred to a tertiary hospital. 
 
3.3 Data Source 
Extraction of information from the original patients’ files and other log books at the MRRH 
medical records was done with the assistance of the hospital gynaecologist and his team 
who did the screening. Women came to the health facility spontaneously as a result of the 
cervical cancer awareness campaign and others were followed in the HIV clinic, 
gynaecology clinic and outpatients’ clinics. The following information was sorted out from the 
files: Socio-demographic characteristics, age at screening, cervical appearance at 
screening, treatment, referral status and outcomes, HIV status, HAART usage and CD4 T 
cells count if previously known case of HIV/AIDS, method of screening used, age at 
menarche, age at sexual debut and first delivery, marital status, education level, occupation, 
contraceptive history and parity [19]. 
 
3.4 Ethical Considerations  
The ethical clearance was requested and permission was sought from the management of 
MRRH. Confidentialities of screened women were highly considered. The obtained 
information will be used for the approved research purposes only. 
 
3.5 HIV 1/2 rapid test 
Tanzania HIV rapid test algorithm for detection of HIV antibodies was used as a standard 
operating procedure [48]. Test one used SD-BiolineTM [49]HIV rapid test using venous blood 
either whole blood or serum as a sample[50]. If the results were non-reactive by seeing one 
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clear red band on the SD-BiolineTM [49], it was reported negative for HIV test[48]. On the 
other hand, if the results were reactive by seeing two or three separated bands on the SD-
BiolineTM [49], then test two using Alere DetermineTM [51]. HIV rapid tests were carried out for 
further evaluations [50]. Furthermore, if the results were reactive by seeing two separate red 
bands on the AlereDetermineTM [51]rapid test, it was confirmed positive for HIV test [48]. 
 
In addition, if the results were negative using Alere DetermineTM [51] HIV rapid test by seeing 
only one red band[50], further evaluations using test three,Uni-Gold TM[52]HIV rapid test 
were carried out [48]. Moreover, if the results were non-reactive using Uni-GoldTM[52]by 
seeing only one red band[50], the final report was negative for HIV test [48], and if the 
results were reactive by seeing two separate red bands using Uni-GoldTM[52], the final report 
was positive for HIV test [48]. 
 
3.6 Visual Inspection Methods VIA and VILI 
Visual inspection with acetic acid (VIA) involved naked-eye inspection of the cervix under 
bright light conditions at least 1 minute after the application of 3-5% diluted acetic acid. The 
screening tests were carried out by a gynaecologists or trained medical doctors, nurses and 
midwives [33]. 
 
A positive result was based on the appearance of well-defined, acetowhite areas in the 
transformation zone [16, 33]. This is the region of the cervix that undergoes metaplastic 
change from columnar epithelium to squamous epithelium [24, 33]. Reported sensitivity of 
VIA ranges from 52% to 79% and specificity of 49% to 88%, which are similar to those for 
cytology. However, VIA is inefficient in detecting lesions located in the cervical canal of the 
uterus [33].  
 
Visual inspection with Lugol’s iodine (VILI) used Lugol’s iodine solution applied to the cervix 
and then it stained glycogen stored in cervical epithelial cells [16, 24]. Neoplastic and 
immature squamous metaplastic epitheliums have less glycogen than the normal mature 
squamous epithelium and so did not turn mahogany brown. Instead they appeared as 
mustard yellow changes, easily recognizable as the acetowhite changes associated with VIA 
[24, 33]. Sensitivity has been reported to vary from 78% to 98% and specificity of 73% to 
91% [24].  
 
Both VIA and VILI have an added advantage of giving immediate results [24, 33]. These two 
methods of visual inspection have been shown to be feasible as a primary means of 
screening for cervical cancer in low income settings and can be used by well trained nurses 
[33].Because of organizational constraints and reported high rates of loss to follow up, 
strategies aiming at screening and treatment in the same visit (‘see and treat’) had been 
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proposed [24]. Effectiveness and acceptability have been evaluated in several studies and 
found to be good [24, 33]. 
 
3.7 Small Biopsy Specimens 
Small loop biopsies were performed mainly for pre invasive lesions, but occasionally early 
invasive carcinomas if highly suspicious were identified [53].Wedge biopsies are usually 
performed for the confirmation and typing of tumours [54] but in this study it was not 
performed due to lack of colposcopy device. Fixation in eosin-tinted formalin to facilitate their 
preservation and identification were performed and all of the biopsy fragments were equally 
processed to ensure there were no fragments lost [55]. 
 
The request forms incorporated the macroscopic description of the specimens and identify 
the areas of the cervix from which the biopsy has originated, i.e. ectocervix, endocervix, or 
transformation zone [56].When a biopsy failed to reveal the source of the abnormal cells, it 
was clearly stated in the request form in order for the pathologist to note and to differentiate 
between a biopsy that was technically adequate but fails to identify a lesion, and a biopsy 
that was technically inadequate [55]. If invasive disease was suspected on the basis of the 
gynaecological examination [57], further levels were advised to examine the patient and 
referral was considered.  
 
Clinical information required on the specimen request form included full patient details, the 
date biopsy taken, cervical screening history (if available), clinical appearance of the cervix, 
site of the biopsy and the results of previous biopsies if any. 
 
3.8 Treatment of Cervical Lesions and Cervical Cancer 
Treatment of precancerous lesions was by either ablative method, the most common being 
cryotherapy, or excisional methods, such as cone biopsy and LEEP[19]. Unlike LEEP, 
cryotherapy does not avail a biopsy sample, and thus it was not possible to know if the 
whole lesion has been destroyed [24].Cryotherapy is easier to use and can be performed by 
nurses, making it more applicable in low income settings [33].However, it may not be 
enough to treat all lesions detected, for example, when the entire squamocolumnar junction 
cannot be visualized, when the lesion is too large for the cryotherapy probe to cover in one 
application, if the lesion extends into the endocervical canal and when there is severe 
cervical atrophy [14, 18, 33]. 
 
Treatment of cervical cancer is dependent on the stage of the disease, age and medical 
state of the patient, tumor characteristics, patients' preferences and resources within the 
health sector of each country [36]. Options can be monotherapy or combined, they range 
from conisation of the cervix, simple hysterectomy with or without lymphadenectomy, radical 
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hysterectomy with pelvic lymphadenectomy, pelvic exenteration, chemotherapy, 
radiotherapy with palliative chemotherapy [24].Treatment at an early stage has the best 
prognosis with the highest cure rates [7].  
 
One disadvantage of ‘see and treat’ screening strategy is overtreatment which has been 
reported to range from 1.2 to 83.3% [33].This is likely to be worse in see and treat strategies 
without a colposcopy before treatment [24]. Colposcopy has been evaluated and could be 
an added asset in improving the effectiveness of ‘see and treat’ programs [24, 33].  
 
The treatment of invasive cervical cancer continues to be a major challenge in many sub-
Saharan African countries, due to the lack of surgical facilities, skilled providers and 
radiotherapy services [58]. Management of women with invasive cervical cancer requires a 
multidisciplinary approach, including: gynecologists, radiation oncologists, medical 
oncologists, pathologists, medical physicists, technicians, nurses and counsellors [24, 58]. 
As the pelvic tumour bulkiness increases the proportion of patients with disease recurrence 
in the pelvis as the only site of treatment failure increases than the proportion of developing 
distant metastases [58]. 
 
3.9 The Operational Definitions 
1.  Exclusion criteria; Patients who were out of the study time frame and those with 
unknown HIV status. 
2.  Live: patients who were alive at the end of treatment or after referral and at the end of 
the study follow-up [19]. 
3.  Dead: patients who died during or at the end of cervical cancer treatment and at the 
end of the study follow up [19]. 
4.  Recurrence: This is defined as the occurrence of the disease symptoms and clinical 
signs six months after optimal treatment. Any occurrence before six months was 
regarded as persistence of the disease[19]. 
5.  Small precancerous lesion: if the entire lesion was visible, the squamo-columnar 
junction was visible, and the lesion was not cover more than 75% of the ectocervix 
[59]. 
6.  Extensive/large lesion: if the lesion extends beyond the cryoprobe being used, or 
extends more than 2 mm into the cervical canal or into the vaginal wall [59]. 
7. Suspicious of cervical cancer; Any abnormal mass around the cervical os or a 
cauliflower-like growth or an ulcer; fungating mass with postmenopausal bleeding, post 
coital bleeding, vaginal bleeding, nonspecific vaginal bleeding, abdominal pain with 
foul smelling vaginal discharge, severe weight loss, obstructive uropathy, or ascites in 
the 12 months prior [19, 60] 
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3.10 Follow-up of Women after Treatment 
Follow-up of patients who had cryotherapy or LEEP was passive, in that they were 
encouraged and expected to return to the clinics if they experienced symptoms such as 
fever for more than 2 days, severe abdominal pain, heavy bleeding unrelated to menses, or 
bleeding with clots[19].Clients were given appointment cards to remind them about the next 
appointment. Those who had a biopsy taken during LEEP treatment were scheduled to 
return of their results after diagnosis at a tertiary hospital. Those who were VIA/VILI negative 
were advised to seek re-screening after 3 years, except for HIV positive women and those 
with positive VIA/VILI results who were scheduled to return yearly [19]. All women who were 
suspicious of cervical cancer disease were referred to a tertiary hospital for further 
pathological evaluations[19]. 
 
3.11 Data Management and Statistical Analysis 
The record audits were done from the data logbook with follow up details of all patients’ 
information and other details were noted from the original files, coded and then entered into 
the SPSSTM computer program version 20 (SPSS Inc.Chicago, Illinois) to create a data 
base.Further analysis of the coded data base and categorical comparisons were performed 
with chi-square test and fisher’s test on different occasions.Test statistics were evaluated 
with a significance level of p<0.05. 
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CHAPTER 4 
 
4.0 RESULTS AND DISCUSSION 
4.1 Results 
A total of 536 women were screened for cervical cancer using VIA or VILI methods at MRRH 
for a period of 3 years. The baseline characteristics of these women according to their social 
demographic status are summarized in Table 1.  
 
Table 1: Socio-demographic characteristics of study subjects (N=536) 
Parameter Characteristics       n % 
 
Age Groups 
 
 
Marital status 
 
 
 
Occupation 
 
 
 
 
 
 
Education level 
 
 
 
 
 
Parity 
 
 
 
Age of sexual 
debut 
21-45 
46-70 
≥ 71 
 
Married 
Widowed/Single 
Divorced/Separated 
 
Business 
Peasant 
Employed 
Farmer 
Student 
Others 
 
Non Formal 
College 
University 
Secondary 
Primary 
 
0-3 
4-7 
≥8 
 
13-16 
17-20 
≥21 
416 
114 
6 
 
298 
170 
68 
 
171 
129 
123 
65 
17 
31 
 
197 
115 
102 
70 
52 
 
              360 
145 
31 
 
             248 
225 
63 
77.6 
21.3 
1.1 
 
55.6 
31.7 
12.7 
 
31.9 
24.1 
22.9 
12.1 
3.2 
5.8 
 
36.8 
21.5 
19 
13.1 
9.7 
 
              67.2 
27.1 
5.2 
 
            46.3 
42 
             11.7 
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Table 1 shows the socio-demographic features of the study population. The age of the study 
population ranged from 21 to 79 years, with a median age of 39 years (± 10.5SD); majority 
of the study subjects 416 (77.6%) were in the age group 21-45 years. Most of the patients, 
171(31.9%) were doing small scale businesses while majority 197 (36.8%) had no formal 
education. In addition, 360 (67.2%) women had a number of children from 0 to 3 while 31 
(5.2%) women had equal or more than 8 children. Of all women screened, 248 (46.3%) had 
the age of sexual debut between 13 and 16 years. 
 
Women who were suspected for ICC were all referred to a tertiary hospital and underwent 
further pathological investigations. Among the 121 women with positive cervical visual 
inspection with VIA or VILI, extended/large lesions were found in 52.5% of HIV-positive 
women and 25% of HIV-negative women (Figure 4). The prevalence of cervical 
precancerous lesions in HIV positive women was 55.5%, which was higher than the 14.7% 
found in HIV negative women. Cervical cancer screened positive results according to the 
age groups of all screened women are summarized in (Figure 5). 
 
In multivariate analysis, an association was found between the HIV positive status and the 
VIA/VILI positive results (p<0.001, OR 9.7, 95% CI 5.6-16.8).In addition, there was an 
association between the HIV status and suspicious of cervical cancer disease (p<0.001, OR 
3.4, 95% CI 1.7-6.8).There was no statistical association found between HIV status and late 
cervical cancer stage (p >0.05) (Table 2). 
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Figure 4:  A flow chart summary showing all screened women distributed according to their 
HIV status, VIA/VILI results and methods of treatment used. (19 women with 
unknown HIV status were removed). 
 
Figure 4 depicts the flow chart summary of the screened women according to their HIV 
status, VIA/VILI results and the method used for the treatment of precancerous lesions. Of 
all screened women, 110(21.3%) were HIV positive and 407(78.7%) were negative for HIV. 
Among HIV positive women, 61(55.5%) had VIA/VILI positive results. Moreover, in HIV 
positive women, 32(52.5%) had extensive precancerous lesions and were treated with LEEP 
while 29(47.5%) had small precancerous lesions and were treated with cryotherapy 
procedure. 
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Figure 5:   Cervical cancer screening positive results distributed according to the age 
groups of all screened women. 
 
Figure 5 shows the VIA/VILI positive results according to age groups. Of all VIA/VILI 
screened positive women, 58(47.9%) were in the age group between 30 and 39 years and 
42(34.7%) women were in the age group between 40 and 49 years.  
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Table 2: Summary of the VIA results, treatment used, HIV status and cervical cancer      
status with the p-values, confidence intervals and Odds Ratios 
 
 
VIA results 
VIA/VILI negative 
VIA/VILI positive 
Suspected cancer 
Cervical cancer stage 
No cancer 
Stage I&II 
Stage III&IV 
Cervical Appearance 
Normal 
Cervicitis 
Pre-cancerous lesions 
Suspected cancer 
Treatment used 
No treatment 
Cryotherapy 
Leep 
 
 
Positive results 
VIA/VILI negative 
VIA/VILI positive 
Suspected cancer 
 
 
VIA/VILI negative 
VIA/VILI positive 
Suspected cancer 
 
 
 
VIA negative 
VIA positive 
Suspected cancer 
 
 
VIA/VILI negative 
VIA/VILI positive 
                         HIV status 
 HIV negative (%) HIV positive (%) Pa C.I OR 
          296(72.7) 
60(14.7) 
51(12.5) 
 
          14(38.9) 
24(68.6) 
9(81.8) 
 
299(73.5) 
  4(0.98) 
53(13) 
 51(12.5) 
 
          349(83.9) 
43(71.7) 
15(25) 
         31(28.2) 
61(55.5) 
18(16.5) 
 
22(61.1) 
10(28.6) 
2(18.8) 
 
36(32.7) 
2(1.8) 
54(49.1) 
18(16.4) 
 
49(11.8) 
29(47.5) 
32(52.5) 
    Ref. 
<0.001 
<0.001 
 
Ref. 
0.0078 
0.0127 
 
Ref. 
0.0814 
<0.001 
<0.001 
 
Ref 
<0.001 
<0.001 
 
5.6-16.8 
1.7-6.8 
 
 
0.09-0.8 
0.02-0.88 
 
 
0.51-27.7 
4.91-14.62 
1.47-5.81 
 
 
2.65-8.71 
7.32-31.88 
 
  9.7 
3.4 
 
 
0.27 
0.14 
 
 
4.2 
8.5 
2.9 
 
 
4.8 
15.2 
                   Age at screening 
21-45 years >45 years  
Ref. 
0.0276 
<0.001 
 
 
0.26-0.97 
1.81-5.85 
 
 
0.51 
3.25 
273(65.4) 
107(25.9) 
36(8.7) 
70(61.4) 
14(12.3) 
30(26.3) 
                 CD 4 T-cells count 
CD4 ≥300  CD4 <300  
   Ref 
  0.5952 
0.0352 
 
 
0.47-3.57 
0.86-31.07 
 
 
1.28 
4.9 
21(67.7) 
36(59) 
3(16.7) 
10(32.3) 
22(36.1) 
7(38.9) 
                          Parity 
0-3 Children >3Children  
Ref. 
0.7465 
<0.001 
 
 
 0.67-1.73 
1.89-5.79 
 
 
1.08 
3.3 
      245(68.1) 
        85(23.6) 
        30(8.3) 
        99(56) 
        36(21) 
        40(22.7) 
                   Age at sexual debut 
                 ≥21                   < 21  
    Ref. 
0.005 
 
 
1.15-2.49 
 
  
1.69 
             155(56.4) 
              70(25.5) 
156(56.4) 
119(43.3) 
*Fisher exact test was considered in cells values less than 5 
*All cases with unknown status and none confirmed cervical cancer diagnosis were disregarded 
 
Table 2 shows the summary of the findings in comparison with the p-values,confidence 
intervals and odds ratios. Apart from HIV positive serostatus, other more common risk 
factors for having positive VIA/VILI test or suspicious of cervical cancer found in our study 
were early age at sexual debut (OR 1.69, 95% CI 1.15-2.49, p=0.005), high parity [61] (OR 
3.3, 95% CI 1.89-5.79, p <0.001 ), age above 45 at screening [60, 62] (OR 3.25, 95% CI 
1.81-5.85, p< 0.001) and CD4 T-cells count of less than 300 cells/mm3 (OR 4.7, 95% CI 
0.86-31.07, p =0.0352). 
24 
 
 
 
Table 3: Summary of the study objectives and the findings 
Objectives HIV positive  HIV negative 
 
Prevalence of  
precancerous   
lesions (%) 
 
 
55.5(n=110) 
 
14.7(n=407) 
Prevalence of 
exensive/large 
precancerous lesions(%) 
             52.5(n=61)                25(n=60) 
 
 
Prevalence of Invasive 
Cervical cancer(%) 
 
Risk factors for the   
extensive cervical lesions 
and suspicious of cancer 
 
             35.3(n=34) 
 
 
Low CD 4 T-cells count,high 
parity,early age at sexual 
debut 
 
70.2(n=47) 
 
 
Early age at sexual 
debut,high parity,age at 
screening 
 
Table 3 shows the summary of findings, according to the study objectives.The prevalence of  
precancerous lesions was greater in HIV positive women than in HIV negative 
women.Moreover, the prevalence of extensive cervical precancerous lesions was twice in 
HIV positive women compared to HIV negative women.However,the prevalence of invasive 
cervical cancer is lower in HIV positive women than in HIV negative women. 
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4.2 Discussion 
 
The present study provides the first comparative retrospective analysis on the influence of 
HIV/AIDS on the precancerous lesions and ICC between HIV positive and HIV negative 
women in Morogoro region, primarily using VIA or VILI screening and then pathological 
evaluations after referral to a tertiary hospital. Considering the spread of  HIV epidemic 
among women in Tanzania [25], an increase in cervical abnormalities could be expected, 
and our observations support the policy of integrating routine screening of HIV infected 
women for cervical cancer in all hospitals in the country. 
 
The prevalence of cervical precancerous lesions was 55.5% in HIV positive women and only 
14.7% in HIV negative women.This shows and supports the fact that HIV positive women 
develop more cervical precancerous lesions compared to HIV negative women (p<0.001, 
OR 9.7, 95% CI 5.6-16.8).This finding reinforces the previous evidences adding results from 
a different study population to the current existing similar findings.  
Our findings on the prevalence of precancerous lesions are higher than the previous studies 
done in Tanzania so far.In the study done in HIV positive women in 2013 by Kafuruki et al 
[63], found the prevalence of precancerous lesions by 26%, Mwakionja et al [64] found the 
incidence of precancerous lesions by 38.3% in HIV positive women and 34% in HIV negative 
women while Balandya et al [65], found a prevalence of precancerous lesions by 42.2% in 
HIV positive women. Alltogether, these results show that the impact of the cervical 
precancerous lesions is increasing in HIV positive women in different study populations with 
time. 
 
The high prevalence of cervical precancerous lesions in the present study could also be 
explained by the fact that our study used lower CD4 count up to 200 cells/mm3 compared to 
others who used CD4 count of 351 cells/mm3 [64, 65] or 450 cells/m3 [63]. The lower CD4 
cell count and advanced stage of HIV could be responsible for the higher  prevalence of 
cervical precancerous lesions seen in our study [65, 66]. Kafuruki et al [63], however,found a 
reduced prevalence of cervical precancerous lesions from 26.8% to 16% when further 
proved by cytology.This might be due to high sensitivity and overdiagnosis hence 
overtreatment of VIA/VILI screening in the detection of cervical precancerous lesions [60, 
62, 67]. The same effect like this has been seen also in a study done in HIV positive women 
screened initially by VIA and later by cytology in Cambodia by Raguenaud et al [68]. 
 
In the present study,also the prevalence of extensive/large cervical precancerous lesions 
was twice in HIV positive women compared to HIV negative women [64, 69]. In Africa, a high 
prevalence of CIN of 76% among HIV infected women has been observed in Lusaka, 
Zambia [70, 71]. The probable explanation could be HIV induced immune-suppression as 
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the CD4 count was as low as 165 cells/mm3 compared to our study of which the lowest 
baseline CD4 count was 200 cells/mm3. 
 
However, the prevalence of invasive cervical cancer was the reverse, lower in HIV positive 
women than in HIV negative women (Table 3).This might be probably due to long duration of 
disease development as it takes 10 to 15 years from precancerous lesion to develop into 
ICC.Therefore, for a screening program like this and others, it would be very difficult to find a 
high prevalence of the ICC in screened women unless a clear follow up of  positive women 
could be done in 10 to 15 years which is very difficult in normal settings. For instance,in a 
HIV clinic based case control study conducted by Mwakigonja et al [64] found the 
prevalence of the ICC was higher in HIV positive women (5.8%) and lower (2%) in HIV 
negative women but the p-value was not statistically significant (p=0.6). Furthermore, they 
used cases in HIV clinics and many of the HIV positive patients had been at the clinics for 
more than 25 years on HAART compared to the controls who were just HIV negative from 
the general population in a cervical cancer screening program like ours. 
 
The pathology results of invasive cervical cancer seen in this setting emphasize the 
importance of introducing a continuous screening program and cancer registry for cervical 
cancer. Despite of being at risk of cervical cancer, none of the participants in this study had 
previously been screened for the disease. This is a major concern in many developing 
countries, including Tanzania, where continue cervical cancer screening is largely 
unavailable, leading to late presentation with advanced cervical cancer disease [60, 72, 73]. 
In addition, the comparison with other similar studies reported from different study 
populations in the world (Table 4) found out that the prevalence and incidence of 
precancerous cervical lesions were higher in HIV positive women than in HIV negative 
women. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
 
 
 
Table 4: Comparison 
of our findings with 
simmilar studies 
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Table 4 shows the comparison of the findings with other 11 similar studies according to the 
objectives of the current study.The present study has similar findings with van Bogaert et al 
[74] and Horo et al [69] in terms of prevalence of the ICC being higher in HIV negative 
women than HIV positive women. 
 
Comparing our findings with Mwakigonja et al [64], Kafuruki et al [63] and Balandya et al [65] 
all done in Tanzania as well, it shows that the incidence of precancerous lesions were higher 
in HIV positive women while decreased in HIV negative women [47, 75].This further shows 
that generally the amount of new cases of women with cervical precancerous lesions are 
increasing in Tanzania.It has been hypothesized that since more women with HIV may 
survive longer due to access and use of HAART therefore the incidence of cervical cancer is 
likely to be increased in the HIV epidemic areas [74, 76]. 
 
In a study done in the USA in 1994, after 6 months of follow-up, cytology and biopsy 
confirmed that pre-invasive cervical squamous intraepithelial lesions (CIN) were detected in 
13% of the 398 HIV-infected women, compared with 4% of the 307 uninfected women [77]. 
In the same study, high-grade SIL (CIN II, III) was detected in 7% of the HIV infected group 
and in 1% of the uninfected group. However, it is difficult also to ascertain the actual 
incidence of cervical cancer in HIV infected women in HIV endemic countries where the 
burden of cervical cancer is higher, but cancer registries for proper documentation, data 
source and follow up is still very scanty [75, 78] ,this was one of the obstacles we faced in 
our study. 
 
Of the numerous cervical cancer screening studies that have been performed among HIV 
infected women in industrialized settings, most have found significantly higher rates of pre-
invasive disease when compared to HIV negative women [7, 47, 70].For example in Pune, 
India, where 1,044 incident cases of cervical cancer were reported during 1996–2000, the 
highest prevalence of 33% of HPV 16/18 which are high risk HPV genotypes known to 
cause cervical cancer was found in HIV infected women  [73, 79]. 
 
However, so far the incidence of cervical cancer among HIV infected women in the 
industrialized world has been unchanged since the introduction of HAART [80, 81].                  
The incidence of HPV induced diseases has increased rather than decreased since the 
introduction of HAART [75, 82]; HAART restores the immune response to AIDS-defining 
opportunistic infections such as Cytomegalovirus and Kaposi’s sarcoma associated virus; 
25% of the HIV infected CIN1 subjects on HAART still progressed to CIN2+, and HIV-
infected patients with CIN2+ often do not show regression when treated with HAART [75, 
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80, 83]. Moreover, currently there are no data available to shed light on the effect of HAART 
on the incidence of invasive cervical cancer in HIV positive women [75, 84]. 
 
Regression of CIN1 and CIN2+ depends on the type of HPV (oncogenic or not) rather than 
on immunocompetence [85]. The longer survival of HIV infected patients related to HAART 
may have a proportionally greater impact on the risk of HPV related cancers than the partial 
reversal of immunosuppression that occurs with HAART [41, 68, 83]. 
 
In the present study, the duration since HIV diagnosis was not determined, in contrary to a 
study done by Kreiss et al [86] which showed that women living with HIV infection for more 
than two years were more likely to carry high risk HPV infections, which could result in CIN 
and hence ICC, compared to women who had been HIV infected for less than a year. 
 
In comparison (table 4), a study done in Ivory coast by Horo et al [69] had the lowest  
findings on the incidence of precancerous lesions in both HIV positive (9%) and HIV 
negative (3.9%)  although the incidence was almost doubled in HIV positive women. Another 
study by Moodley et al [18] , done in South Africa, reports the highest incidence of 
precancerous lesions in both HIV positive women (59.9%) and HIV negative women 
(31.6%).This might be due to more cervical cancer endemic study population, study design 
and sample size in their study compared to others. The second higher incidence in our 
comparison (table 4) was observed in a study done in Thailand by Chalermchockcharoenkit 
et al  [87] which found an incidence of cervical precancerous lesions by 37% although only 
in HIV positive women. 
 
In our study, in Tanzania, the prevalence precancerous lesions is very high if compared to 
the studies by Moodley et al [18] reported in South Africa, Park et al [88] reported  in Korea 
,Teixeira et al [89] reported  in Brazil and Chalermchockcharoenkit et al [87] reported in 
Thailand. However, all show high prevalence of precancerous lesions in HIV positive 
women.The high prevalence of precancerous lesions in HIV positive women in the present 
study shows that the lesions are widespread in the population and there is a risk factor that 
plays a role in the high findings which might be the HIV infection although any other 
confounding factors like early age of the debut, very low CD4 count used and presence of 
high risk HPV genotypes might add an effect. Also, this indicates that invasive cervical 
cancer is a chronic disease since it takes longer time to develop [74] that might be why we 
have found a high prevalence of cervical precancerous lesions in HIV positive women but 
low prevalence of ICC in the same study population. Another reason might be due to the fact 
that we have conducted our study in a very high HIV endemic area in the region [19]. 
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Another important comparative observation noted was in a study reported in South Africa by 
Moodley et al [18] where they got high incidence (59.9% to 31.6%) of cervical precancerous 
lesions, but low prevalence (50% to 13%) in both HIV positive and HIV negative 
women,respectively while in our study we have got high prevalence (55.5% to 14.7%)  of 
precancerous lesions, in HIV positive and HIV sero negative women, respectively.This could 
be explained probably due to extensive development of well organized cancer registries and 
continue cervical cancer screening and treatment of precancerous lesions present in South 
Africa compared to the lack of these services in Morogoro,Tanzania hence there are 
accumulations of precancerous lesions in both HIV positive and HIV negative women.  The 
implementation of cancer registries and continuous screening and treatment of cervical 
precancerous lesions in women should be invented in Tanzania especially in Morogoro 
region so as to reduce the observed high prevalence. 
 
According to our study, HIV positive women were 15.2 times more at risk to develop 
extended/large precancerous lesions (p< 0.001, 95% CI 7.3-31.9)  which keeps them in a 
very high risk to develop invasive cervical cancer if they are also co-infected with a high risk 
HPV [12]. In a similar study reported in Ivory coast by Horo et al [69] found the risk of 
developing extended/large precancerous lesions was 2.28 times more (p< 0.001, 95% CI 
1.6-3.3) in HIV positive women than in HIV negative women.This risk is low compared to our 
study findings and different factors may account for this observation, such as study 
population, sample size, HAART use and amount of CD4+ T-cell count used [74]. 
 
In Thailand, Chalermchockcharoenkit et al [87] found the prevalence of extensive 
precancerous lesions in HIV infected women was 68.7%  which is very high compared to 
52.5% in our findings.This might be due to the fact that they used lower CD4 count. For 
example, more than 230 (28.9%) women had CD4 count less than 200 cells/mm3.This also 
was observed in a study reported in Dar Es Salaam,Tanzania by Kapiga et al [72] where 
they found that the risk of SIL was significantly increased among women with CD4+ cell 
count of less than 200 cells/mm3 (p<0.001, OR 6.15, 95% CI 1.19-41.37).The relationship 
between HIV and cervical cancer is unique in that women at risk of both conditions share 
common socio-behavioral patterns, such as early onset of sexual intercourse, high number 
of sexual partners and smoking [75, 90]. 
 
In our study, the prevalence of invasive cervical cancer was almost doubled in HIV negative 
women (50.8%)  compared to HIV positive women (26.7%) . This finding is similar to the 
study done in South Africa by van Bogaert [74] in which the prevalence of the ICC was 
30.6% in HIV positive women and 57% in HIV negative women.One hypothesis is that HIV 
infected women might die early from HIV-related opportunistic infections before the period of 
time needed for development of invasive cervical cancer. In another study reported in China, 
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by Chan et al [91], there was no patient with newly diagnosed cervical cancer  found to have 
HIV infection by screening. In addition, Chan et al [91] and Branca et al [92] both found no 
cervical cancer patient who was found to have undiagnosed HIV through screening in their 
study, in which all HIV cases were previously identified as HIV positive before the diagnosis 
of cervical cancer or precancerous lesions, findings that are different with our study. The 
reason might be due to different study design, study population and the study area.  
 
ICC has been recently included among AIDS-defining conditions, even though it has not 
significantly increased in the HIV positive female population [76, 90], contrary to what 
happens to other tumours such as KS and NHL [75, 83].The incidence of invasive cervical 
cancer is expected to increase over time due to the fact that HIV infected women will survive 
long enough to exceed the latency time of these tumours [75, 83, 90]. 
 
For instance, in the study by Kahesa et al [90] reported in Tanzania, it was concluded that 
HIV-1 is  associated with ICC (p<0.001). However, as previously mentioned, in this way, a 
careful surveillance is needed because of a significant increase in pre-neoplastic lesions and 
survival improvement among HIV infected women in the last decade [93, 94]. For example, 
in  an American series study, 16 of 84 (19%) patients with invasive cervical carcinoma were 
HIV seropositive, of which 14 (85%) were asymptomatic for HIV infection according to 
current CDC definitions [83]. 
 
Another example similar to our findings is published in a report from western Kenya  from a 
population study of 4308 HIV infected women who underwent cervical cancer screening , the 
prevalence of the ICC was only 1.3%, with the majority having had stage IA1 disease at the 
time of diagnosis [95]. On the other hand, as mentioned earlier, a study done also in 
Tanzania by Mwakigonja et al [64] found the reverse of ours as the prevalence of the ICC 
was 5.8% in HIV positive women and 2% in HIV negative women, although the p-value was 
not statistically significant [64].This might be explained further as due to the small sample 
size, they used only170 women compared to our study sample size which was 536 women. 
Also they conducted their study in the HIV clinics only which could lead to a bias since the 
women were known HIV positive patients for long periods. 
 
Again, another study reported in Ivory coast by Horo et al [69], found the similar results to 
ours as the prevalence of the ICC was 2.3% in HIV positive women and 15% in HIV negative 
women. This might suggest that immunosupresion from HIV infection is not the only 
determinant of invasiveness of cervical cancer development, hence the involvement of the 
ICC as ADIs is still debatable [74]. According to van Bogaert et  al [74],data suggest that 
immunosuppression may lead to higher levels of HPV replication with resulting higher HPV 
DNA levels and increased incidences of LGSIL and HGSIL. However, there have been no 
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similar findings in ICC; cellular genetic changes rather than immunosuppression may be the 
driving force of progression into ICC.  
 
Moreover, as HIV infection is much more common among young people, one could expect 
an earlier onset of the process of cervical cancer in this group [66]. For example, in our 
retrospective study, we found one woman with stage II cervical cancer disease at the age of 
28, however, this is the first youngest case ever to be reported from Tanzania to date. Our 
findings are similar to those of Lomal-isa et al [96] and Gichangi et al [4] who reported that 
HIV seropositive women in South Africa and Kenya, respectively presented with invasive 
cervical cancer 10 years earlier than HIV negative women. 
 
Immunosuppression is strongly associated with preinvasive cervical lesions, but the 
progression to the ICC is not solely associated with immunosuppression [74]. In HIV-infected 
women study by Harris et al [42] found the hazard ratio of developing any preinvasive lesion 
was 1.2 if the CD4+ T-cell count was >500/μL, which was similar to HIV negative controls. 
On the other hand, a  Zimbabwean study, however, concluded that only HR HPV, and not 
HIV, was associated with CIN [97]. The rate of ICC in women with AIDS might be unrelated 
to immunosuppression only and therefore, not biologically associated with HIV [41]. 
 
 The reversal of immunosuppression following HAART would have a dramatic effect on the 
natural history of cervical preinvasive lesions [98], but data on the effects of HAART in this 
regard are mixed [30, 99]. The increased risk of HIV infected women to CIN2 may be due to 
different factors such as high exposure to risk factors like coitarche, number of sexual 
partners, oral contraceptive use, a direct effect of HIV or a molecular interaction between 
HIV and HPV [92, 100]. 
 
The study of HPV induced cervical neoplasia in HIV infected women is complex and is 
riddled with contradictory reports [74].For instance, it has been reported, as already 
mentioned, that the incidence of cervical cancer has not decreased in the HAART era and 
that clinical research has not shown a clear benefit of HAART (Figure 6) in decreasing HPV 
related cervical disease in HIV infected women [99, 101].  
 
However, contrary to Hawes et al [102], no impact on the development of SIL was evidenced 
for CD4+ T-cell counts by Heard et al [103], although in our study, we observed the increase 
of cervical precancerous lesions in HIV positive  women with CD4 T-cell count of less than 
300 cells/mm3 (p=0.0352, 95% C.I 0.86-31.07, OR 4.9). 
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Figure 6: A diagram to summarize the findings and further suggestions 
 
Figure 6 depicts the relationship between HIV, HPV infection and the cervical precancerous 
lesions and cervical cancer with the risk factors which contribute to the development of the 
interaction. The actual intersection between the two co-infections and the development of 
the ICC is still questionable with a lot of schools of thoughts from many studies. For 
instance, van Bogaert et al [74] clearly questioned the involvement of  ICC among acquired 
immune deficiency syndrome-defining illnesses. 
 
Human papillomavirus (HPV), the necessary cause of cervical cancer, is endemic in Africa 
[104]. Although our study did not evaluate the involvement of HPV subtypes in the 
precancerous lesions, it has been isolated in most cases of precancerous lesions and 
cervical cancer in all parts of the world. Epidemiological studies have shown that the 
association of genital human papilloma virus with cervical cancer is strong, independent of 
other risk factors, and consistent in several countries [105]. 
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HPV 16/18 is estimated to account for 70% of all cervical cancers worldwide, although the 
estimated HPV 16/18 fraction is slightly higher in more developed (72–77%) than in less 
developed (65–72%) regions [106]. About 41–67% of high-grade squamous intraepithelial 
lesion (HSIL), 16–32% of low-grade squamous intraepithelial lesion (LSIL) and 6–27% of 
atypical squamous cells of undetermined significance (ASCUS) are also estimated to be 
HPV 16/18 positive, thus highlighting the increasing relative frequency of HPV 16/18 with 
increasing cervical lesion severity [106]. 
 
Many of the factors that increase both HPV acquisition and promote the oncogenic effect of 
the virus are also very widespread in Africa [107]. These include: early marriage, 
polygamous marriages and high parity. Polygamy is reported to increase the risk of cervical 
cancer two-fold and the risk increases with increasing number of wives [108]. This is another 
part of the male factors in addition to prostitution and circumcision that leads to the high 
prevalence of HPV in Sub Sahara Africa including Tanzania [109]. 
 
High parity, which is the norm in some cultures in Africa, is also a recognized HPV-related 
co-factor for the development of cervical cancer [110].The prevalence of HPV has been 
shown to be higher in uncircumcised men than in circumcised men [109]. In a study to 
investigate the association between male circumcision (MC) and high risk human papilloma 
virus (HR-HPV) prevalence, Auvert et al [111] using urethral swabs collected during a period 
of 262 consecutive days among participants from the intervention (circumcised) and control 
(uncircumcised) groups who were reporting for a scheduled follow-up visit reported that HR-
HPV prevalence among intervention and control groups were 14.8% (94/637) and 22.3% 
(140/627),respectively. Further, the multiple HR-HPV prevalence was significantly lower 
among men of the intervention group compared with men of the control group, 4.2% and 
9.9%, respectively. 
 
Male circumcision was strongly associated with lower cervical cancer rates and fewer HIV 
cases, independent of religion [112]. Furthermore, in the same study, male circumcision was 
independently associated with HIV among countries with primarily heterosexual HIV 
transmission, and not among countries with primarily homosexual or injection drug use HIV 
transmission (p<0.001). All these findings suggest that male circumcision is a true protective 
factor that reduces the sexual transmission of HIV and possibly HPV [112]. 
 
Socio-economic factors, worldwide women of low socio-economic status have a greater risk 
of having cervical cancer [113]. Cervical cancer is often referred to as a disease of poverty 
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and of poor women. A recent study in Mali in West Africa showed that within a population 
widely infected with HPV, poor social conditions, high parity and poor hygienic conditions 
were the main co-factors for cervical cancer [17].  
 
Morogoro region also has widespread conditions that encourage substandard living 
conditions [25]. These include natural disasters, famine and drought. These often lead to 
large populations being displaced externally and internally for long periods of time. Under 
these refugees- like conditions, social vices like rapes, prostitution, multiple marriages and 
cohabitation prevail encouraging the transmission of HPV [10]. Most villages of Morogoro 
region are located within the tropical rain forest with difficult terrain as there are lots of 
swampy areas and thick and mountainous forests. This makes access to screening for 
cervical cancer, health education and treatment to be difficult  [25]. 
 
Biological factors like poor nutritional status and infections, for example, malaria, HIV and 
TB, are ravaging in Morogoro region as well as the whole sub-Saharan Africa and have 
made many people immuno-compromised [25]. Several studies have demonstrated the 
association of HIV with HPV. The prevalence of CIN has been estimated to be as high as 
20–40% in HIV positive women [114]. HIV-positive women are more likely to have persistent 
HPV infections than HIV negative women [47]. In a similar study to ours, of 2,198 women 
who attended gynaecological clinics in Abidjan, Côte d'Ivoire, HIV positive women had a 
significantly higher prevalence of squamous intraepithelial lesions (SIL) [9]. Temmerman et 
al [115] reported a five-fold increased risk of high-grade SIL among 513 HIV positive women 
in a family planning clinic in Kenya. Another recently published study from Tanzania showed 
that the prevalence of HIV-1 was much higher among the cervical cancer patients (21.0%) 
than among the controls (11.6%). HIV-1 was a significant risk factor for cancer of the cervix 
(p<0.001, OR 2.9, 95% CI=1.4–5.9) [18]. 
 
Low education on awareness and knowledge of cervical cancer in Morogoro region has 
been observed as another risk factor for the disease. Cervical cancer is yet to be recognized 
as an important public health problem in the region [25]. In Tanzania, priority is given to 
infectious diseases such as malaria, tuberculosis, leprosy, diarrheal diseases, acute 
respiratory infections and HIV/AIDS all of which have preventive and management strategies 
[25]. Several studies have shown poor knowledge of cervical cancer in Sub Saharan Africa, 
which cuts across different literacy levels [116]. For example, among 500 attendees of a 
maternal and child health clinic in Lagos, Nigeria only 4.3% were found to be aware of 
cervical cancer [117].  In 2004, also in Lagos-Nigeria, 81.7% of 139 patients with advanced 
cervical cancer had never heard of cervical cancer before, and 20%, 30% and 10% 
respectively thought the symptoms they had were due to resumption of menses, lower 
genital infection and irregular menses [118].  On the other hand, similar studies in Kenya 
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and Tanzania also reported very poor knowledge of the disease in patients [5, 23]. Poor 
knowledge is not limited to patients alone, however, health care workers who are supposed 
to be better informed do not have good knowledge of the disease either. Education improves 
knowledge and acceptance of preventive measures against cervical cancer [15]. 
 
Poor cervical cancer screening services were another problem seen in Morogoro region. All 
536 women in our study were never screened for cervical cancer before. In a study among 
medical workers in a Ugandan hospital (doctors, nurses and medical students) only 19% of 
the female medical workers had ever had a cervical cancer screening test done. The 
reasons for not having been screened included: not feeling at risk, lack of symptoms, 
carelessness, fear of vaginal examination, lack of interest, test being unpleasant and not yet 
being of risky age. Moreover, 25% of the female respondents said that they would only 
accept a vaginal examination by a female health worker [15].  
 
In a similar study among nurses in a Tanzanian hospital concerning nurses' own cervical 
cancer screening practices most (116/137) of the respondents had never had a Pap smear. 
The most common reasons (54.7%) was not knowing where to go for the test, followed by 
seeing no reason for the test (13.1%), being afraid of the procedure (9.5%) and being afraid 
of bad results (7.3%)[24] .Furthermore, there are very few cervical cancer screening 
services in Tanzania and many of them are based on secondary and tertiary health care 
facilities located in urban areas. Screening in most developing countries like Tanzania is 
mainly opportunistic, characterized by an estimated low coverage, coexisting with over-
screening of women with access to health services, and an absence of quality control 
procedures [24].Policies for cervical cancer screening in most African countries vary and, 
most often nonexistent [15] . 
 
In our study, access to treatment for ICC was limited for patients who were referred, only 
one third of the women with ICC received a TAH, with more than a half having received no 
treatment or being lost to follow-up due to long waiting times, sizeable co-payments, and 
lack of staff availability all contributed to the lack of treatment access. Likewise, in a cervical 
cancer screening program in Kenya for example, when women offered LEEP in the clinic or 
referral for the treatment of suspected cervical cancer or extensive lesions, all eligible 
women chose LEEP performed in-clinic at no cost [95].  In other field reports suggest that 
LEEP referral rates are higher in HIV positive women due to more large lesions seen in this 
population [11, 119]. 
 
The strength of our investigation was that we carried out a large comparative retrospective 
study compare to others already done in Tanzania. The weakness was that we have had to 
rely on the information documented by others like the results of screening and the biopsy 
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diagnosis in case of referred patients.Also, there was no history of behavioural risk factors, 
for example lifetime sex partners and limited availability of post-treatment information 
because of loss to follow-up. Additionally, the clinical protocol did not include an immediate 
post-treatment biopsy to ascertain whether disease found at follow-up was truly new, 
recurrent or attributable to treatment failure. Also the margin status was not assessed as this 
is a known predictor of disease recurrence in the referred LEEP specimens. However all 
these minor shortcomings have no or little confounding effects on our results. 
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CHAPTER 5 
 
5.0 CONCLUSION AND RECOMMENDATIONS 
5.1 Conclusion 
These results indicate the crucial importance of continuous screening of HIV-infected 
women who live in resource constrained settings like Morogoro region in Tanzania. Also, it 
shows that prevention of cervical cancer in HIV positive women must be focused towards 
early detection of cervical abnormalities by VIA or VILI followed by an appropriate treatment. 
Our findings may be an important incentive for all HIV-infected women to be engaged in a 
gynaecological care program. The high prevalence of precancerous lesions in our study is 
one of the highest reported findings in any population worldwide. Therefore, continuous 
cervical cancer screening and treatment services of HIV infected women in Tanzania should 
be implemented to prevent development of HPV-induced ICC. Despite a probable bias and 
minimal confounding factors, our study suggests that HIV seropositive women present 
significantly younger with cervical cancer disease than HIV negative women. This study also 
shows a significant increase in proportion of extended cervical precancerous lesions among 
the reproductive tract cancers of women and changes in mean age of presentation or 
severity of invasive cervical cancer over time. In our study, ICC prevalence in HIV infected 
women has decreased compared to their counterpart, HIV non- infected women. Because 
our sample was somehow representative of HIV infected women seeking antiretroviral 
therapy in the public sector clinics in Morogoro, it strongly suggests the critical need for 
undertaking a concerted effort towards the provision of a cervical cancer screening and 
treatment program that will benefit the average woman accessing these clinics. HPV 
vaccination shows a great promise for the control of cervical cancer in the developing 
countries which have a significant burden of morbidity and mortality due to cervical cancer 
and where difficulties in implementing and sustaining cytology based screening methods 
also do exist .Further studies are needed to determine the crucial relationship of co-
infections between HIV and HPV with the development of  invasive cervical cancer, however 
to current many studies show an open debate for the involvement of cervical cancer as an 
AIDS defining illness. Therefore, HIV/AIDS has a highly statistical significant association 
(p<0.001) and high influence on the development of cervical precancerous lesions in HIV 
positive women, however its direct involvement in the progression to ICC could be 
questionable, especially in the HAART era as we have also found in our study, as others 
already did, the number of women with ICC were almost doubled in HIV negative women 
compared to HIV positive women. 
 
 
39 
 
 
5.2 Recommendations 
There is a need to improve the outlook of this condition in Tanzania. There should be 
improvement in attitude towards education needs of the population so as to create and 
improve awareness and knowledge about the disease. Disease prevention requires social 
change, including demographic groups at high risk for disease, appropriate governmental 
authorities, and essential medical personnel. There is a need for sensitization of healthcare 
workers about cervical cancer and the importance of screening for cervical cancer disease. 
Based on studies carried out in countries where organized screening and cancer registries 
are available, it is known that screening tendencies can be influenced by cultural beliefs, the 
social position of women, characteristics of the health care system, the health workers’ 
attitudes towards screening and society comprehension of the screening process [120].  
 
Embarrassments about undergoing a pelvic examination, fear of the procedure and society 
local believes that little can be done to prevent cancer diseases are other factors that might 
decrease screening participation [13]. Lower socio-economical background, lack of feasible 
health facilities and low literacy also compromise participation in the voluntary screening for 
cervical cancer [13, 23]. The gender of health care professionals and the limited time that 
they allocate to community education on the importance of screening for cervical cancer 
may negatively influence screening participation as well [121]. 
 
Formulation and ensuring compliance with national program guidelines is an essential step 
towards significantly reducing the burden of cervical cancer [122]. This type of service does 
not reach women most at risk for example, older women aged 35–60 years or HIV infected 
women especially to those who live in rural areas [70]. Cytology-based screening, which is 
used in developed countries, is a resource intensive, and difficult to apply in many countries 
in sub-Saharan Africa because of poor health care infrastructure and lack of resources [123]. 
For example, in Morogoro region where we conducted our study, there are no 
cytopathologists, cytoscreeners, cytotechnicians and even in other nearby regions some of 
them have inadequate training and quality control as well. Histopathological services are 
extremely limited in many sub-Sahara African countries [102]. Malawi, for example, a 
country with a cervical cancer incidence rate of 47 per 100,000 women, had one pathologist, 
one colposcope, no cyto-technicians and no facilities for cervical cancer screening or 
treatment in 5 regions of the country in 2001 [124]. This situation in Malawi is not much 
different compared to Tanzania.  
 
A good example also was seen in Botswana, where a national cervical cytology screening 
committee was formed in 1996 with a role in planning and advising the government. Just six 
years later a national guidance document for the national cervical cytology program was 
drawn up and implemented. In this short duration of time public awareness has been 
40 
 
 
successfully raised, resulting in an increased uptake of Pap smears from 5000 per year 
before the start of the program with an impressive 32,000 per year in 2009 [125].This 
problem was not limited to Botswana as many African countries like Tanzania have similar 
inadequate resources to treat patients even when abnormal cervical cytology is detected.  
 
Training curricula medical personnel need to be improved in order to include more practical 
cervical cancer screening skills [126]. There is a need to change attitudes that screening is 
only for gynaecologists. For opportunistic screening to work, health care workers in other 
departments need to be sensitized on the importance of cervical cancer screening and they 
need to refer all eligible women who come into their care for screening without much delay 
[15]. Nurses in developed countries for example, play a role in cancer prevention and 
participate in cervical cancer screening by carrying out Pap smear tests. Due to the lack of 
logistics and scarcity of gynaecologists and pathologists in Tanzania, nurses should be used 
effectively and in all centres in the prevention of cervical cancer, by being enabled to collect 
biopsy specimen and the use of the visual inspection technique which is less costly and 
does not require high expertise [24]. 
 
Visual inspection methods are, however, subjective methods and prone to different 
interpretations by different observers, depending on experience and competence [119, 127]. 
Other screening methods include HPV DNA assay which has been shown to be even 
superior to Pap smear test and colposcopy [128] but its implementation in Tanzania is still 
not feasible probably due to limited availability of funds, pathology laboratories and expertise 
in the diagnostic process [25].For example in a study published in Portugal by Silva et al 
[129] shows that self-sampling using HPV DNA testing may be a good alternative in 
substitution of the vaginal speculum examination by a clinician or dependence on highly 
trained pathologists instead self-sampling can be used as a tool for primary screening of 
HPV infection in young asymptomatic women.  
 
However, VIA and VILI, as a form of population-based screening has shown better 
assistance so far across the continent [130]. VIA is similar to colposcopy in that 4% acetic 
acid is applied to the cervix and any acetowhite lesion is visualized, although with VIA there 
is no magnification [131]. Candidates with suspicious lesions are selected for treatment. 
Studies have shown the sensitivity of VIA to be the same as that of Pap smear while its 
specificity is lower than 85% [132].The specificity is also noted to be even lower among HIV 
positive patients possibly due to high rates of co-infections in the lower genital tract [84].  
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In developed areas with low mortality rates from cervical cancer, organized screening 
programs had great impact on the reduction of cervical cancer mortality. Time trends in 
mortality from cervical cancer in Denmark, Finland, Iceland, Norway, and Sweden since the 
early nineteen fifties were investigated in relation to the extent and intensity of organized 
screening programs in these countries [133]. In all five countries, the cumulative mortality 
rates (0-74 years) fell between 1965 and 1982. In Iceland, where the nationwide program 
has the widest target age range, the fall in mortality was greatest (80%)[133].  
 
Finland and Sweden have nationwide programs also; the mortality fell by 50% and 34%, 
respectively. In Denmark, where about 40% of the population is covered by organized 
programs, the overall mortality fell by 25%, but in Norway, with only 5% of the population 
covered by organized screening, the mortality fell by only 10% [133]. The results support the 
conclusion that organized screening programs have had a major impact on the reduction in 
mortality from cervical cancer in the Nordic countries [133].For instance, in the majority of 
low-income countries like Tanzania, cervical cancer screening program has proven difficult 
to sustain, in large part probably because of its reliance on highly trained cytotechnologists, 
high-quality laboratories and well established infrastructures to support up to 3 visits for 
screening, colposcopic evaluation of abnormalities and treatment [25]. 
 
Recent studies suggest that alternate screening strategies that use HPV DNA testing or 
simple visual screening methods may be more practical in some areas of the world like Sub 
Saharan Africa including Tanzania. Also regardless of initial screening test strategies that 
enhance the linkage between screening and treatment, there should be functional cancer 
registries in order to minimize loss to follow-up, lack of organized data, inconsistency of the 
screening activities and lack of specialized units for the task force as it was observed in our 
study. Additionally, economic evaluations of all the above alternatives have concluded that 
they are promising [134].  
 
 HPV vaccination to the recommended target population will reduce the disease incidence in 
the future [25]. The high cost of the vaccines is a constraint on low resource countries that 
have a high incidence of the disease like Tanzania. It has been submitted that the vaccines 
if given to girls before onset of sexual activity, have the potential to dramatically reduce the 
incidence of HPV infection and therefore cervical cancer[135]. However, the vaccine is of 
little value to the population of women who have already become sexually active as it cannot 
eradicate the virus if already present or retard the growth of incipient cancer[135].  
 
Prevention and early diagnosis through vaccination and screening requires effective 
mobilization of the target groups and this has been a problem in developing countries like 
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Tanzania since cultural, emotional barriers and practical needs are among the main reasons 
as to why women choose not to be screened [25]. Addressing these barriers and needs will 
help to increase women’s awareness and willingness to seek services. Screening, 
treatment, and follow-up services need to address women’s cultural, emotional, practical 
needs and concerns. 
 
Community-based education approach as a way of building capacity to all women and 
promote their participation will help to reduce fear and misunderstandings about cervical 
cancer screening and treatment. Making women’s experiences with screening services more 
positive, ensures greater follow-up rates and increases the likelihood that they will share 
information about their good experience with peers.  
 
Effective public messages to improve cervical cancer awareness are needed. Messages 
should be targeted to reach community at higher risk of cervical cancer. Recognized barriers 
to women’s participation in screening may include: little understanding of the disease, limited 
access to screening services, shame and fear of a vaginal exam, fear of death from cancer, 
lack of community and family support [19]. Common misconceptions about cervical cancer 
include the fact that people often do not know that it is preventable. 
 
Community meetings, posters, pamphlet newspaper advertisements or articles, radio and 
television messages can help to spread cervical cancer awareness to the society. Key 
sources of information include peers who have received messages or been screened, 
leaders or members of women’s groups, midwives and traditional healers, community health 
promoters, community leaders, nurses, nurse practitioners and medical doctors. 
 
Places to reach women such as local women’s groups community centers, women’s 
workplaces, places of worship, health facilities, maternity clinics, schools and markets 
should be targeted to spread key cervical cancer prevention messages which may include 
the facts that good health practices can help prevent cancer, cervical cancer develops slowly 
and is preventable, screening can detect and treat the precancerous cervical lesions before 
they progress to invasive cervical cancer, women aged 30 and older or HIV positive are 
more likely to develop cervical precancerous lesions hence invasive cervical cancer than 
younger women, women in their thirties and forties should be screened and that the 
screening procedure is relatively simple, quick, and not painful. Screening test positive is not 
a death sentence, rather it provides the opportunity to eliminate abnormal cells before they 
become invasive. 
 
Community health or outreach workers who can facilitate communication at the community 
level should be highly encouraged. Counselling by health care providers can both inform 
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women and help them talk to their families. In order to ensure women’s positive experiences 
with screening, there is a need to build and maintain positive provider-client relationships. 
This is needed because women are more likely to participate when they are treated well, 
health care providers are sensitive, responsive and respectful. 
 
Screening services and procedures should be friendly to women to ensure that  women with 
positive experiences will become advocates when talking to other women. Important 
counselling tips include listening and encouraging women to express their concerns being 
sensitive to cultural and religious considerations expressing support through non-verbal 
communication, such as nodding, keeping messages simple and answering questions 
directly, calmly, and in a reassuring manner and providing adequate information to remind 
them of the instructions.  
 
Having female health care providers in settings where women are uncomfortable with male 
health care providers, if possible could help. Ensuring affordability of the services and 
confidentiality are essential practice. Local languages should be incorporated into the 
counselling medium. Advisory teams of women and other key community leaders can be 
consulted in order to deliver a package that will meet women’s cultural, emotional and 
practical needs.  
 
High parity is associated with increased incidence of HPV infection leading to increased 
cases of cervical cancer. Education on the effective family planning methods can help in 
improving the general living condition of the people. This will eventually lead to a sizeable 
population that can be easily reached with cervical cancer control programs. 
 
Early onset of sexual activities among teenage girls in Morogoro region is high.                           
This predisposes such girls to high risk of developing cervical cancer. The promotion of the 
proper use of condoms through sex education programs in early school days can also help 
in reducing the transmission of HPV in the region. Closely linked to this is the issue of male 
circumcision, which should be encouraged among those with low level of practice. 
 
Pre-requisites for cervical cancer screening, infrastructure, funding and training needs in 
Morogoro region might include; screening points have to be as many as possible and, the 
implementation of continuous cervical cancer screening in all HIV clinics in Tanzania. 
Sustainable funding for screening programs is important and, one way to achieve this could 
be for donors to insist that they would only fund a cervical cancer screening program if the 
government agreed to provide funding support for the program to continue after set‐up 
funding ended. 
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Building up political will and support for national funding support towards cervical cancer 
screening would be required. Community advocates and the media would also need to be 
mobilized in a public health approach. Raising public awareness about the causes of 
cervical cancer, the impact of HIV/AIDS on the precancerous lesions and why treatment 
would be important. 
 
If possible, screening should be integrated into existing programs, such as programs for 
breast cancer screening, sexual health programs and many others. This might go hand in 
hand with the training of health professionals to take smear tests and/or HPV tests and 
training of pathologists to read smear tests would also be critical. 
 
Evaluation and cost effectiveness of cervical screening should focus on; training, are 
programs easy to staff? Should pap smears be abandoned for developing countries due to 
lack of people to read them? Work must be done by another health care level other than 
doctors? Brain drain is another issue; we must address the retention of health care 
personnel. Cost, need more interaction with health economists, sustainability of the project?  
 
We must look into different financial flows, the idea of marketing campaigns and alternate 
financing schemes to raise substantial funds. Is coverage feasible of “mother‐daughter” 
screening and vaccination project? Feasibility of self‐screening? Political will; is there a need 
to sell a product to the policy makers? Screening must be made part of country’s health 
policy. Demonstration projects are a good way to show political leaders the efficacy of 
screening programs. MDG goals 4 and 5 (reduction in child mortality and improvement in 
maternal health) are a useful platform to use or argue that HPV is part of maternal health. 
 
Creating a climate for informed decision-making in screening and vaccination program, the 
following must be considered; informed consent has to be tailored appropriately to 
population. Informed consent means different things in different situations and with different 
people, so it has to be appropriate to the population. Cervical cancer screening should 
become part of routine health care. Most policy makers are not yet aware of the cost/toll of 
cervical cancer in their countries. Consequently, the development of cancer registries is 
important. There is a need to show politicians that the impact of screening would be seen 
now and it is ideal.  
 
Survivors’ stories and the family stories of the women who have died of cervical cancer need 
to be told. Doctors and nurses should also tell stories about cervical cancer. We should not 
be afraid to tell individual stories; these are the ones that touch people. 
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Policy and advocacy: raising awareness , supporting champions, advocates and funders to 
take action and assisting in the development of policies and guidelines to create an 
environment supportive of a practical, sustainable and cost-effective national strategy for 
comprehensive prevention of cervical cancer [120]. Developing training resources and 
conducting competency-based training for health care providers and supervisors. 
 
Initiation of the sustainable service delivery system that will address integration, 
procurement, repair and maintenance of equipment, information systems for monitoring and 
evaluation (M&E), consistent supportive supervision, high-quality services and care of the 
screening programs should be highly encouraged [136]. Also, referral systems should be 
strengthened within the health systems to ensure that women receive the appropriate follow-
up and treatment. 
 
Capacity building which involves initial training, investments must be made in supportive 
supervision, coaching and quality assurance. Mid-level providers (nurses, midwives) should 
be used for effective delivery of VIA/VILI and cryotherapy services. Strengthening of M&E in 
all healthcare facilities that conduct cervical cancer screening must be supported to collect 
quality data and more important the use that data regularly to improve service provision. 
Lastly, the maintenance of cryotherapy equipment and other necessary supplies should be 
included in project planning. 
 
Efforts to improve awareness of the target population can result in early detection of 
precancerous lesions, leading to improved survival from cervical cancer in Tanzania.              
A combination of community-based, facility-based and media-based strategies can be used 
to create awareness and inform women [137].  
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